| Affymax and Takeda Report Additional Analyses of Peginesatide Phase 3 Studies ... - MarketWatch (press release) |
|
|
MarketWatch (press release) The findings, presented at the American Society of Nephrology's (ASN) Kidney Week, provide further detail on the frequency of adverse events of peginesatide and epoetin alfa or beta, as well as information on the relationship between peginesatide and |